Jiangsu Hengrui Medicine (600276) Stock Price, Fundamentals & Analysis

What 600276 does

Jiangsu Hengrui Medicine (600276) is a stock listed on the Shanghai Stock Exchange in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. The company researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. Its portfolio spans oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. Founded in 1970 and headquartered in Lianyungang, China, it employs 20,602 people. It is part of the CSI 300 index and operates alongside peers such as Shanghai Pharmaceuticals Holding (601607), United Imaging (688271), BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE (603392), WuXi AppTec (603259), Zhangzhou Pientzehuang Pharmaceutical (600436), Guangzhou Baiyunshan Pharmaceutical Holdings (600332), and Fosun Pharmaceutical (600196).

Key numbers explained

• 44.86 CNY is the current share price, the amount you would pay for one share right now.
• The trailing P/E ratio of 38.7 shows how much investors are paying per unit of past earnings; a higher P/E ratio often reflects higher growth expectations.
• The forward P/E ratio of 29.1 uses expected future earnings, which can be more relevant for growth-oriented companies.
• Earnings per share, trailing 12 months of 1.16 CNY represents the portion of the company's profit allocated to each outstanding share over the last year.
• The dividend yield of 0.38% indicates the annual dividend payment as a percentage of the current share price; it is a measure of cash return to shareholders.
• The ex-dividend date of May 27, 2026 is the cutoff: you must own the stock before this date to receive the next dividend.
• 16% of earnings paid out as dividends shows the payout ratio, or how much of profit is returned to shareholders versus retained for reinvestment.
• Beta of 0.04 suggests the stock's price has historically been far less volatile than the overall market.
• The 52-week range of 41.89 – 71.66 shows the lowest and highest traded prices over the past year, with the current price near the lower end.
• Revenue, trailing 12 months of 32.56 mld. CNY and revenue growth, year over year of 13% indicate the scale and top-line expansion of the business.
• Profit margin of 24.9% and operating margin of 31.6% reflect how much of each revenue unit remains as profit after costs and operating expenses.
• Return on equity of 14.5% measures how effectively the company generates profit from shareholders' invested capital.
• Debt-to-equity ratio of 0.1 indicates a very low level of debt relative to equity, suggesting a conservative capital structure.
• Price-to-book of 4.78 compares the market price to the company's book value per share.

What to watch

• The price change over the last 52 weeks of -35.2% highlights a significant decline from the year-ago level, which can reflect sector rotation, market sentiment, or company-specific developments.
• The price change today of -1.58% shows short-term movement that may be tied to broader market swings or news flow.
• A low beta of 0.04 and a modest dividend yield of 0.38% suggest the stock is typically viewed as a defensive, low-volatility holding rather than a high-growth or high-income play.
• The debt-to-equity ratio of 0.1 and strong profit margin of 24.9% point to a solid balance sheet and efficient operations, which investors often monitor for resilience during economic cycles.
• As a Healthcare stock focused on drug manufacturing, Jiangsu Hengrui Medicine can be influenced by regulatory approvals, pipeline updates, and pricing policies in China and internationally.